Kursprognose für Kairos Pharma Ltd (KAPA)KAPAKairos Pharma Ltd

Alphio's KAPA stock price prediction model matches the current Kairos Pharma Ltd tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.49 (-1.34%). The 1-week path is $0.50 (+1.20%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Kairos Pharma Ltd (KAPA) is not a good buy right now due to its significant financial struggles and poor technical indicators. The stock is currently priced at $0.49, which is a staggering 90.31% down year-to-date and 92.38% down over the past year. Additionally, the RSI is at 35.563, indicating that the stock is nearing oversold territory, but this does not guarantee a rebound. The forward P/E ratio is 0, reflecting a lack of expected earnings growth, and the company has reported negative net income consistently, with a loss of $1,654,000 in Q1 2026. The main risk is the company's ongoing financial losses, with an EPS of -0.55 expected in the next earnings report, which could further depress the stock price.

Kairos Pharma Ltd (KAPA) last closed at $0.4949, gaining +8.86%. These facts feed the 1-day and 1-week KAPA price prediction above.